How different is the once-weekly teriparatide from the daily one or the same?
作者信息
Takeuchi Yasuhiro
机构信息
Toranomon Hospital Endocrine Center, Japan.
Okinaka Memorial Institute for Medical Research, Japan.
出版信息
Osteoporos Sarcopenia. 2019 Jun;5(2):27-28. doi: 10.1016/j.afos.2019.06.004. Epub 2019 Jun 20.
Abstract
摘要
相似文献
1
How different is the once-weekly teriparatide from the daily one or the same?每周一次的特立帕肽与每日一次的特立帕肽相比，有何不同或相同之处？
Osteoporos Sarcopenia. 2019 Jun;5(2):27-28. doi: 10.1016/j.afos.2019.06.004. Epub 2019 Jun 20.
2
Comparison of the effects of once-weekly and once-daily rhPTH (1-34) injections on promoting fracture healing in rodents.每周一次与每日一次注射重组人甲状旁腺激素（1-34）对促进啮齿动物骨折愈合效果的比较。
J Orthop Res. 2018 Apr;36(4):1145-1152. doi: 10.1002/jor.23750. Epub 2017 Nov 20.
3
Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.每周一次特立帕肽治疗糖皮质激素诱导骨质疏松症患者的疗效：TOWER-GO 研究。
J Bone Miner Metab. 2021 May;39(3):446-455. doi: 10.1007/s00774-020-01171-5. Epub 2020 Nov 19.
4
The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration.特立帕肽对非典型股骨骨折后骨愈合加速的影响：每日和每周给药的比较。
Osteoporos Int. 2018 Dec;29(12):2659-2665. doi: 10.1007/s00198-018-4658-7. Epub 2018 Aug 13.
5
Effect of dosing frequency of teriparatide (PTH 1-34) on bone formation in rats: comparison of bone metabolism marker levels.特立帕肽（PTH 1-34）给药频率对大鼠骨形成的影响：骨代谢标志物水平的比较。
J Toxicol Sci. 2018;43(7):435-442. doi: 10.2131/jts.43.435.
6
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.特立帕肽每周 2 次注射与每周 1 次注射治疗骨质疏松症患者的疗效比较研究：TWICE 研究。
Osteoporos Int. 2019 Nov;30(11):2321-2331. doi: 10.1007/s00198-019-05111-6. Epub 2019 Aug 8.
7
Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study.每周一次特立帕肽治疗糖皮质激素诱导骨质疏松症的疗效：TOWER-GO 研究的事后分析。
Mod Rheumatol. 2022 Apr 18;32(3):634-640. doi: 10.1093/mr/roab034.
8
Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.每周一次的特立帕肽可降低具有各种骨折风险患者的椎体骨折风险：特立帕肽每周一次疗效研究（TOWER）试验的亚组分析
J Bone Miner Metab. 2014 Jul;32(4):441-6. doi: 10.1007/s00774-013-0505-2. Epub 2013 Nov 9.
9
Utility of radius bone densitometry for the treatment of osteoporosis with once-weekly teriparatide therapy.每周一次特立帕肽治疗骨质疏松症时桡骨骨密度测定的效用
Osteoporos Sarcopenia. 2018 Mar;4(1):29-32. doi: 10.1016/j.afos.2018.02.001. Epub 2018 Mar 5.
10
Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.甲状旁腺功能减退和低骨量血液透析患者每周一次使用特立帕肽：一项前瞻性研究。
Osteoporos Int. 2016 Apr;27(4):1441-1450. doi: 10.1007/s00198-015-3377-6. Epub 2015 Nov 2.
引用本文的文献
1
Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial.从双膦酸盐类药物转换为每周一次的特立帕肽后糖皮质激素性骨质疏松症的改善：一项随机开放标签试验
J Clin Med. 2022 Dec 30;12(1):292. doi: 10.3390/jcm12010292.
本文引用的文献
1
Impact of patient background factors on the treatment efficacy of once-weekly teriparatide.患者背景因素对每周一次特立帕肽治疗疗效的影响。
Osteoporos Sarcopenia. 2019 Jun;5(2):51-56. doi: 10.1016/j.afos.2019.04.001. Epub 2019 May 16.
2
Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk.每周一次皮下注射特立帕肽治疗高骨折风险骨质疏松症患者在实际临床实践中的安全性和有效性。
Osteoporos Sarcopenia. 2019 Jun;5(2):44-50. doi: 10.1016/j.afos.2019.06.002. Epub 2019 Jun 26.
3
Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide.皮质骨孔隙率增加与每日而非每周给予等量特立帕肽有关。
Bone. 2017 Jun;99:80-84. doi: 10.1016/j.bone.2017.03.042. Epub 2017 Mar 18.
4
Frequency of Teriparatide Administration Affects the Histological Pattern of Bone Formation in Young Adult Male Mice.特立帕肽给药频率影响成年雄性小鼠的骨形成组织学模式。
Endocrinology. 2016 Jul;157(7):2604-20. doi: 10.1210/en.2015-2028. Epub 2016 May 26.
5
Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.特立帕肽、地诺单抗及联合治疗对周围骨密度、微结构和估计强度的比较效应：DATA-HRpQCT研究
J Bone Miner Res. 2015 Jan;30(1):39-45. doi: 10.1002/jbmr.2315.
6
Romosozumab in postmenopausal women with low bone mineral density.罗莫佐单抗治疗绝经后低骨密度妇女。
N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.
7
The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT.每周一次的特立帕肽对通过CT评估的髋部结构和生物力学特性的影响。
Osteoporos Int. 2014 Mar;25(3):1163-72. doi: 10.1007/s00198-013-2596-y. Epub 2013 Dec 18.
8
Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women.单次注射特立帕肽对绝经后妇女骨转换标志物的影响。
Osteoporos Int. 2013 Jan;24(1):219-26. doi: 10.1007/s00198-012-2159-7. Epub 2012 Oct 24.
9
Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.随机特立帕肽[人甲状旁腺激素(PTH)1-34]每周一次疗效研究(TOWER)试验，旨在检查原发性骨质疏松症和高骨折风险患者新椎体骨折减少情况。
J Clin Endocrinol Metab. 2012 Sep;97(9):3097-106. doi: 10.1210/jc.2011-3479. Epub 2012 Jun 20.
10
PINP as an aid for monitoring patients treated with teriparatide.PINP 可作为监测特立帕肽治疗患者的辅助手段。
Bone. 2011 Apr 1;48(4):798-803. doi: 10.1016/j.bone.2010.12.006. Epub 2010 Dec 17.
Zotero 插件